title: Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
abstract: It is established that efflux transporters of the ATP-binding cassette (ABC) superfamily can affect the pharmacokinetics of drugs through mechanisms pertaining to drug absorption, elimination, and distribution. To characterize the role of multiple transporters in topotecan's pharmacokinetics, total (lactone+carboxylate) and lactone forms were measured by liquid chromatography/tandem mass spectrometry (LC/MS-MS) in plasma, bile, urine, and feces following intravenous administration at doses of 1 and 4 mg/kg to eight mouse strains: C57BL/6 [wild-type (WT)], Abcb1(-/-), Abcc2(-/-), Abcc4(-/-), Abcg2(-/-), Abcc2;Abcb1(-/-), Abcc2;Abcg2(-/-), and Abcc4;Abcg2(-/-). Compared with WT mice and at both dose levels, the plasma areas under the curve for topotecan lactone were not significantly different in the Abcc2(-/-), Abcc4(-/-), and Abcb1(-/-) strains, whereas significant differences were found in Abcg2(-/-), Abcc2;Abcb1(-/-) (only at the high dose), Abcc4;Abcg2(-/-), and Abcc2;Abcg2(-/-) mice and ranged from 2.1- to 3.3-fold higher. Consistent with these changes, the fecal and biliary excretion of topotecan was reduced, whereas renal elimination was elevated in Abcg2(-/-)-based strains. Similarly, the Abcc2;Abcb1(-/-) strain also had elevated renal elimination and reduced fecal excretion of topotecan lactone. This was more pronounced at the 4 mg/kg dose level, suggesting possible saturation of Abcg2. The Abcc4 transporter was found not to be a major determinant of topotecan pharmacokinetics. It is concluded that Abcg2 has the most significant effect on topotecan elimination, whereas both Abcb1 and Abcc2 have overlapping functions with Abcg2. As such it is relevant to examine how polymorphisms in these transporters influence topotecan activity in patients and whether coadministration of transport modulators could positively affect efficacy without increasing toxicity.
authors: Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors: Amit K
authors: AK
authors: Tiwari
authors: Rong
authors: R
authors: Zhang
authors: James M
authors: JM
authors: Gallo
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D004195:Disease Models, Animal; D057809:HEK293 Cells; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D000089762:Multidrug Resistance-Associated Protein 2; D059004:Topoisomerase I Inhibitors / Q000493:pharmacokinetics; D019772:Topotecan / Q000493:pharmacokinetics*
chemical_list: C000715087:ABCC2 protein, human; D018528:ATP-Binding Cassette Transporters; D000089762:Multidrug Resistance-Associated Protein 2; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
references: Cancer Res. 2003 Oct 1;63(19):6447-52
references: 14559835
references: J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):217-22
references: 21112407
references: Clin Pharmacokinet. 1996 Aug;31(2):85-102
references: 8853931
references: Mol Interv. 2009 Jun;9(3):136-45
references: 19592674
references: Clin Cancer Res. 2007 Nov 1;13(21):6440-9
references: 17975156
references: Annu Rev Biochem. 2002;71:537-92
references: 12045106
references: J Natl Cancer Inst. 2000 Dec 6;92(23):1934-40
references: 11106685
references: Drug Metab Dispos. 2011 Nov;39(11):2155-61
references: 21841039
references: J Med Chem. 1989 Mar;32(3):715-20
references: 2537428
references: Neurosurgery. 2011 Dec;69(6):1272-9; discussion 1279-80
references: 21562434
references: Cancer Metastasis Rev. 2007 Mar;26(1):5-14
references: 17273943
references: Cancer Lett. 2013 Jan 28;328(2):307-17
references: 23063650
references: Cancer Res. 1993 Feb 15;53(4):725-7
references: 8428353
references: Oncologist. 2004;9(1):68-79
references: 14755016
references: Pharm Res. 2005 Nov;22(11):1837-53
references: 16132345
references: J Clin Oncol. 2000 Jun;18(12):2459-67
references: 10856106
references: Mol Cell Biol. 2004 Sep;24(17):7612-21
references: 15314169
references: FEBS J. 2011 Sep;278(18):3226-45
references: 21740521
references: Mol Pharm. 2011 Aug 1;8(4):1292-302
references: 21630681
references: Biochem Biophys Res Commun. 1996 Mar 27;220(3):848-52
references: 8607854
references: J Pharmacol Exp Ther. 2007 Sep;322(3):1246-52
references: 17556638
references: J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):121-42
references: 21104004
references: Cancer Res. 1993 Mar 1;53(5):1032-6
references: 8439950
references: J Hum Genet. 2010 Nov;55(11):731-7
references: 20720558
references: Clin Cancer Res. 1999 Jan;5(1):69-75
references: 9918204
references: J Natl Cancer Inst. 2000 Oct 18;92(20):1651-6
references: 11036110
references: Cancer Res. 2007 Jan 1;67(1):262-8
references: 17210706
references: Anticancer Drugs. 1998 Aug;9(7):587-92
references: 9773801
references: Cancer Res. 2009 Jul 15;69(14):5885-92
references: 19567673
references: Eur J Pharm Sci. 2004 Jan;21(1):25-51
references: 14706810
references: FEBS Lett. 1999 Aug 6;456(2):327-31
references: 10456333
references: Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64
references: 12111113
references: Cancer Biol Ther. 2005 Jun;4(6):650-8
references: 15908806
references: Ann Oncol. 1993 Sep;4(8):673-8
references: 8240998
references: Cancer Res. 1994 Oct 1;54(19):5118-22
references: 7923128
references: Biochem Pharmacol. 2005 Oct 1;70(7):1088-95
references: 16099435
references: J Histochem Cytochem. 1999 Jun;47(6):757-68
references: 10330452
references: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15387-92
references: 12426403
references: Curr Pharm Biotechnol. 2011 Apr;12(4):570-94
references: 21118094
references: Biochem Pharmacol. 2009 Jul 15;78(2):153-61
references: 19427995
references: Cancer Res. 1987 Feb 15;47(4):936-42
references: 3802100
references: J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42
references: 17148776